JP2016189772A5 - - Google Patents

Info

Publication number

JP2016189772A5

JP2016189772A5 JP2016053802A JP2016053802A JP2016189772A5 JP 2016189772 A5 JP2016189772 A5 JP 2016189772A5 JP 2016053802 A JP2016053802 A JP 2016053802A JP 2016053802 A JP2016053802 A JP 2016053802A JP 2016189772 A5 JP2016189772 A5 JP 2016189772A5

Authority

JP

Japan

Prior art keywords

polypeptide fragment

compound

seq

amino acid

subunit

Prior art date

2016-03-17

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000012634 fragment Substances 0.000 claims 37
• 108090000765 processed proteins & peptides Proteins 0.000 claims 36
• 229920001184 polypeptide Polymers 0.000 claims 35
• 102000004196 processed proteins & peptides Human genes 0.000 claims 35
• 150000001875 compounds Chemical class 0.000 claims 28
• 150000001413 amino acids Chemical class 0.000 claims 24
• 238000000034 method Methods 0.000 claims 22
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 20
• 125000003275 alpha amino acid group Chemical group 0.000 claims 17
• 230000000694 effects Effects 0.000 claims 9
• 102000004533 Endonucleases Human genes 0.000 claims 8
• 108010042407 Endonucleases Proteins 0.000 claims 8
• 206010022000 influenza Diseases 0.000 claims 8
• 210000004027 cell Anatomy 0.000 claims 7
• 239000013078 crystal Substances 0.000 claims 6
• 208000036142 Viral infection Diseases 0.000 claims 5
• 230000009385 viral infection Effects 0.000 claims 5
• 101100338269 Caenorhabditis elegans his-41 gene Proteins 0.000 claims 4
• 201000010099 disease Diseases 0.000 claims 4
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
• 239000008194 pharmaceutical composition Substances 0.000 claims 4
• 239000000654 additive Substances 0.000 claims 3
• 239000000969 carrier Substances 0.000 claims 3
• 238000005094 computer simulation Methods 0.000 claims 3
• 238000004519 manufacturing process Methods 0.000 claims 3
• 102000040430 polynucleotide Human genes 0.000 claims 3
• 108091033319 polynucleotide Proteins 0.000 claims 3
• 239000002157 polynucleotide Substances 0.000 claims 3
• 150000003839 salts Chemical class 0.000 claims 3
• WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims 2
• JTPUYUCBHGNBBX-UHFFFAOYSA-N 4-[3-[(4-chlorophenyl)methyl]-1-phenylmethoxysulfonylpiperidin-3-yl]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound C1CCN(S(=O)(=O)OCC=2C=CC=CC=2)CC1(C(=O)C=C(O)C(=O)O)CC1=CC=C(Cl)C=C1 JTPUYUCBHGNBBX-UHFFFAOYSA-N 0.000 claims 2
• XWMHHMXKNMXGDP-UHFFFAOYSA-N 4-[4-[(4-chlorophenyl)methyl]-1-(cyclohexylmethyl)piperidin-4-yl]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound C1CN(CC2CCCCC2)CCC1(C(=O)C=C(O)C(=O)O)CC1=CC=C(Cl)C=C1 XWMHHMXKNMXGDP-UHFFFAOYSA-N 0.000 claims 2
• 241000712892 Arenaviridae Species 0.000 claims 2
• WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
• 108060004795 Methyltransferase Proteins 0.000 claims 2
• 241000150350 Peribunyaviridae Species 0.000 claims 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
• 238000004364 calculation method Methods 0.000 claims 2
• 150000001768 cations Chemical class 0.000 claims 2
• 239000003814 drug Substances 0.000 claims 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
• 150000003384 small molecules Chemical class 0.000 claims 2
• 230000002194 synthesizing effect Effects 0.000 claims 2
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 1
• 239000004471 Glycine Substances 0.000 claims 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
• PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 1
• 108020000999 Viral RNA Proteins 0.000 claims 1
• 125000000539 amino acid group Chemical group 0.000 claims 1
• 210000004899 c-terminal region Anatomy 0.000 claims 1
• 230000001419 dependent effect Effects 0.000 claims 1
• 229940079593 drug Drugs 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 239000003446 ligand Substances 0.000 claims 1
• 229910052749 magnesium Inorganic materials 0.000 claims 1
• 239000011777 magnesium Substances 0.000 claims 1
• 229910052748 manganese Inorganic materials 0.000 claims 1
• 239000011572 manganese Substances 0.000 claims 1
• 238000002156 mixing Methods 0.000 claims 1
• 239000000203 mixture Substances 0.000 claims 1
• 230000035772 mutation Effects 0.000 claims 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
• 125000003386 piperidinyl group Chemical group 0.000 claims 1
• 102000004169 proteins and genes Human genes 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 claims 1
• 230000001105 regulatory effect Effects 0.000 claims 1
• 238000011179 visual inspection Methods 0.000 claims 1